Literature DB >> 12904606

Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis type VI.

Oliver F Strauch1, Jörg Stypmann, Thomas Reinheckel, Elke Martinez, Wilhelm Haverkamp, Christoph Peters.   

Abstract

Mucopolysaccharidosis type VI (MPS VI) is a lysosomal storage disease caused by a deficiency of arylsulfatase B (ASB) which has its function in the sequential degradation of glycosaminoglycans (GAG). Targeted disruption of the ASB gene resulted in a mouse model of MPS VI that has been closely investigated for skeletal and chondral dysplasia. As ocular and cardiac impairment are also clinically important manifestations of the MPS VI syndrome, the present study was initiated for detailed biochemical, histologic and functional analysis of cornea, optic nerve and heart in ASB-deficient mice. Biochemical evidence for GAG-storage could be obtained for liver, kidney, spleen and myocardium as well as for heart valves, cornea and optic nerve from ASB-deficient mice. In MPS VI mice, histology revealed structural impairment of corneal stroma and epithelium as well as a thickening of the heart valves. According to histologic investigations, the optic nerve appeared not to be altered. However, GAG-storage in the dura mater could be demonstrated in MPS VI mice. Heart function was assessed by echocardiography. While the dimensions of MPS VI hearts were not altered, these hearts clearly showed decreased myocardial contraction and a 50% reduction of cardiac output. In addition, insufficiencies in the mitral and aortic valves were detected. Thus, ASB-deficient mice resemble the phenotype of human MPS VI not only in the skeletal but also in the ocular and cardiac symptoms. To our knowledge, these in vivo evaluations of heart function represent the first respective investigation of a MPS VI animal model and should provide a valuable measure for therapy studies in the MPS VI mouse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904606     DOI: 10.1203/01.PDR.0000084085.65972.3F

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  12 in total

1.  Neurologic, gastric, and opthalmologic pathologies in a murine model of mucolipidosis type IV.

Authors:  Bhuvarahamurthy Venugopal; Marsha F Browning; Cyntia Curcio-Morelli; Andrea Varro; Norman Michaud; Nanda Nanthakumar; Steven U Walkley; James Pickel; Susan A Slaugenhaupt
Journal:  Am J Hum Genet       Date:  2007-10-02       Impact factor: 11.025

2.  Age and gender related reference values for transthoracic Doppler-echocardiography in the anesthetized CD1 mouse.

Authors:  Jörg Stypmann; Markus A Engelen; Constanze Epping; Harold V M van Rijen; Peter Milberg; Christian Bruch; Günter Breithardt; Klaus Tiemann; Lars Eckardt
Journal:  Int J Cardiovasc Imaging       Date:  2006-03-04       Impact factor: 2.357

3.  Murine hyaluronidase 2 deficiency results in extracellular hyaluronan accumulation and severe cardiopulmonary dysfunction.

Authors:  Biswajit Chowdhury; Richard Hemming; Sabine Hombach-Klonisch; Bruno Flamion; Barbara Triggs-Raine
Journal:  J Biol Chem       Date:  2012-11-21       Impact factor: 5.157

4.  Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer.

Authors:  Gabriella Cotugno; Patrizia Annunziata; Alessandra Tessitore; Thomas O'Malley; Anita Capalbo; Armida Faella; Rosa Bartolomeo; Patricia O'Donnell; Ping Wang; Fabio Russo; Meg M Sleeper; Van W Knox; Steven Fernandez; Leah Levanduski; John Hopwood; Elvira De Leonibus; Mark Haskins; Alberto Auricchio
Journal:  Mol Ther       Date:  2010-11-30       Impact factor: 11.454

5.  Therapeutic homology-independent targeted integration in retina and liver.

Authors:  Patrizia Tornabene; Rita Ferla; Manel Llado-Santaeularia; Miriam Centrulo; Margherita Dell'Anno; Federica Esposito; Elena Marrocco; Emanuela Pone; Renato Minopoli; Carolina Iodice; Edoardo Nusco; Settimio Rossi; Hristiana Lyubenova; Anna Manfredi; Lucio Di Filippo; Antonella Iuliano; Annalaura Torella; Giulio Piluso; Francesco Musacchia; Enrico Maria Surace; Davide Cacchiarelli; Vincenzo Nigro; Alberto Auricchio
Journal:  Nat Commun       Date:  2022-04-12       Impact factor: 17.694

6.  The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.

Authors:  Gabriele Giacomo Schiattarella; Giuliana Cerulo; Valeria De Pasquale; Pasquale Cocchiaro; Orlando Paciello; Luigi Avallone; Maria Paola Belfiore; Francesca Iacobellis; Daniele Di Napoli; Fabio Magliulo; Cinzia Perrino; Bruno Trimarco; Giovanni Esposito; Paola Di Natale; Luigi Michele Pavone
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

7.  Similar therapeutic efficacy between a single administration of gene therapy and multiple administrations of recombinant enzyme in a mouse model of lysosomal storage disease.

Authors:  Rita Ferla; Pamela Claudiani; Gabriella Cotugno; Paola Saccone; Elvira De Leonibus; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2014-04-11       Impact factor: 5.695

8.  Sensory-motor behavioral characterization of an animal model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI).

Authors:  Paola Saccone; Gabriella Cotugno; Fabio Russo; Rosa Mastrogiacomo; Alessandra Tessitore; Alberto Auricchio; Elvira De Leonibus
Journal:  Sci Rep       Date:  2014-01-10       Impact factor: 4.379

9.  Low-dose Gene Therapy Reduces the Frequency of Enzyme Replacement Therapy in a Mouse Model of Lysosomal Storage Disease.

Authors:  Marialuisa Alliegro; Rita Ferla; Edoardo Nusco; Chiara De Leonibus; Carmine Settembre; Alberto Auricchio
Journal:  Mol Ther       Date:  2016-09-23       Impact factor: 11.454

10.  Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.

Authors:  Eugeni Entchev; Ingrid Jantzen; Philippe Masson; Stephanie Bocart; Bruno Bournique; Jean-Michel Luccarini; Andre Bouchot; Olivier Lacombe; Jean-Louis Junien; Pierre Broqua; Mireille Tallandier
Journal:  PLoS One       Date:  2020-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.